[1] 陈灏珠,林果为,王吉耀. 实用内科学.北京:人民卫生出版社,2013.
[2] Dultz G,Piiper A,Zeuzem S,et al.Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther,2015,41:459-466.
[3] 司小北,蓝宇.长期使用质子泵抑制剂的不良反应.药物不良反应杂志,2015,17:218-221.
[4] Kinoshita Y,Ishimura N,Ishihara S.Advantages and disad-vantages of long-term proton pump inhibitor use. Neurogastroenterol Motil,2018,24:182-196.
[5] 史晓晓,郑松柏.质子泵抑制剂长期应用的安全性研究进展.中国新药与临床杂志,2016,35:387-392.
[6] Cole HL,Pennycook S,Hayes PC.The impact of proton pump inhibitor therapy on patients with liver disease. Aliment Pharmacol Ther,2016,44:1213-1223.
[7] Cunningham R,Jones L,Enki DG,et al.Proton pump inhibitor use as a risk factor for enterobacteriaceal infection: a case-control study. J Hosp Infect,2018,100:60-64.
[8] Macnaughtan J,Jalan R,et al.Editorial:proton pump inhibitor therapy and liver disease progression-more cause for concern? Aliment Pharmacol Ther,2018,47:304-305. |
